Although vaccination represents the most promising way to stop or contain the coronavirus disease 2019 (COVID-19) pandemic and safety and effectiveness of available vaccines were proven, a small number of individuals who received anti-SARS-CoV-2 vaccines developed a prothrombotic syndrome. Vaccine-induced immune thrombotic thrombocytopenia (VITT) can be triggered by the adenoviral vector-based vaccine, whereas lipid nanoparticle-mRNA-based vaccines can induce rare cases of deep vein thrombosis (DVT). Although the main pathogenic mechanisms behind this rare phenomenon have not yet been identified, both host and vaccine factors might be involved, with pathology at least in part being related to the vaccine-triggered autoimmune reaction. In this review, we are considering some aspects related to pathogenesis, major risk factors, as well as peculiarities of diagnosis and treatment of this rare condition.
© 2021 Elsevier B.V.
- Autoimmune Reaction
- Adenoviral Vector-based Vaccine
- Lipid Nanoparticle-Mrna-Based Vaccine
- Vaccine-Induced Immune Thrombotic Thrombocytopenia
- Vaccination/adverse effects
- SARS Virus
- COVID-19 Vaccines
- Viral Vaccines
- Lipid nanoparticle-mRNA-based vaccine
- Adenoviral vector-based vaccine
- Autoimmune reaction
- Vaccine-induced immune thrombotic thrombocytopenia